Oncology

“If you were to ask me what the 1 magic thing would be, it would be that we would adopt a concept of 1 team, one fight nationally, and that we would be able to have our structures and our coordination of care.”

Patients with advanced solid tumors may be able to stay on treatment with saruparib longer compared with other approved PARP inhibitors, thereby improving efficacy.

Results from 3 DESTINY trials led to the accelerated approval of fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive solid tumors.

Further research may be needed to help determine the underlying mechanisms of polybrominated diphenyl ether exposure contributing to the risk of cancer-related mortality.

If possible, targeting the BER pathway for drug sensitivities may increase therapeutic options for managing solid cancers, wrote Channing Paller, MD.

An updated guideline from ASCO highlights appropriate use of vaccines for patients with cancer receiving treatments such as CAR T-cell therapy or B-cell depleting therapy.

Investigators will evaluate the preliminary efficacy and safety of NST-628 in adult patients with solid tumors harboring mutations in the RAS-MAPK pathway as part of a phase 1 trial.

Cancer vaccines are a “cross-cutting approach” that may be applicable across several cancer types, according to Catherine J. Wu, MD.

mRNA may be a potential modality for developing cancer-based vaccines, according to Catherine J. Wu, MD.

Analyzing the KRAS mutation across various cancer types may be a worthwhile target when using a cancer vaccine or immunotherapy, says Catherine J. Wu, MD.

Edward S. Kim, MD, MBA, and Richard T. Lee, MD discuss how integrative oncology techniques such as acupuncture have impacted patient quality of life at their practice.

Primary care physicians cannot afford to dismiss younger people who present with symptoms of cancer in the face of increasing cancer incidence, according to Monique Gary, DO, MSc, FACS.

In a recent Hot Topics article, reimbursement rates for Medicare physicians are discussed, and how it will impact their practice.

Denosumab biosimilars have been approved by the FDA as Wyost and Jubbonti across various reference indications.

Julie M. Vose, MD, MBA, discusses the pros and cons of patients having early access to electronic medical records.

Robert A. Winn, MD, discusses financial initiatives for expanding access to anti-cancer treatment and how collaborations with professional organizations may spread awareness of cancer disparities.

Panitumumab plus modified FOLFOX6 appears to increase survival among patients with metastatic colorectal cancer and circulating tumor DNA that has no gene alterations in the PARADIGM trial.

Authors of a study from the American Cancer Society estimate over 2 million new cancer cases in 2024.

Findings highlight a need for individualized risk evaluation for venous thromboembolism and prophylaxis regimens for patients receiving surgery for different types of cancer.

Emphasizing precise terminology in clinical studies may improve the transparency and accuracy of information presented at oncology conferences.

Diane M. Simeone, MD highlights the importance of multidisciplinary care, surgical practices, and early detection in pancreatic cancer care.

The AACR Health Disparities Report highlights the changes needed to achieve health equity for patients with cancer.

Robert A. Winn, MD, gives insight into how institutions and community practices can improve access to cancer care.

Findings from a study raise concerns for the outcomes of individuals who experience an adverse financial event prior to a cancer diagnosis.

The FDA set a Prescription Drug User Fee Act date of June 15, 2024 for repotrectinib as a treatment for those with advanced or metastatic solid tumors harboring an NTRK gene fusion.

A 77% increase in the risk of developing cancer by 2050 was determined by the World Health Organization in a recent survey.

FDA initiatives such as the Food and Drug Omnibus Reform Act will set goals and specify measures for improving representation in pediatric cancer clinical studies.

Starting April 1, 2024, Diane Simeone will be the new director of UCSD Moores Cancer Center.

Data from the phase 2 DESTINY-PanTumor02 trial support the supplemental biologics license application for trastuzumab deruxtecan as a treatment for those with metastatic HER2-positive solid tumors.

Therapies like yoga, music therapy, acupuncture, and natural health remedies have proven to be beneficial in mitigating anxiety and depression in adults with cancer, according to Linda E. Carlson, PhD, RPsych.